Botanix announces regulatory approval of ECCLOCK® gel, 5% (Sofpironium Bromide) in South Korea
Botanix has announced that sublicensee Dongwha Pharm. Co., Ltd. has received regulatory approval for ECCLOCK® gel, 5% (Sofpironium Bromide) in South Korea.
Dongwha – Korea’s first and oldest pharmaceutical company – will commercialise ECCLOCK in the Korean market and add the product to its extensive range of prescription and over-the-counter products. The launch of ECCLOCK is expected to occur in the first quarter of 2026, and the product will be manufactured at Kaken’s Shizuoka plant in Japan.
